cenegermin

Cenegermin is a recombinant human nerve growth factor (rhNGF) produced by recombinant DNA technology. It is formulated as an ophthalmic solution used to treat neurotrophic keratitis, a degenerative condition of the cornea caused by reduced corneal innervation and impaired healing.

NGF promotes survival and growth of corneal neurons and supports epithelial cell migration and wound healing, helping restore corneal integrity after injury or disease.

It is indicated for the treatment of neurotrophic keratitis in adults and in pediatric patients aged 3 years and older. The recommended regimen is one drop in each affected eye six times daily for eight weeks. Dosing is performed with clean hands, removing contact lenses prior to administration; avoid touching the dropper to the eye, and discard any unused solution after the dosing period ends.

Store refrigerated; do not freeze.

Common adverse events include eye pain, corneal epithelial defect, keratitis, conjunctival hyperemia, tearing, and blurred vision. Rare events may include corneal edema or ocular inflammation. Caution with active ocular infections or contact lens use.

Brand name and availability: cenegermin is marketed under the name Oxervate in several regions and is supplied as cenegermin-bkbj in some markets. It is produced by Dompé and is used for neurotrophic keratitis when corneal healing is impaired due to nerve damage.

See also: Nerve growth factor; Neurotrophic keratitis.